Summary
A new experimentalin-vitro model is described, which was used for studying prostacyclin (PGI2)-thromboxane A2 (TXA2)-interactions.
Langendorff hearts of guinea pigs are perfused at constant volume with Krebs-Henseleit buffer and washed human platelets (4x108/min). PGI2 and TXA2 release are measured by bioassay. The cardiac and coronary function and the myocardial oxygen consumption are continuously monitored. The platelet count in the cardiac effluent can be measured and the cAMP content has been estimated. This model might be a useful tool for studying the roles of PGI2 and TXA2 in platelet activation and coronary perfusion in terms of endogenously synthesized substances.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dusting, G. J., S. Moncada, J. R. Vane: Prostaglandins, their intermediates and precursors: Cardiovascular actions and regulatory roles in normal and abnormal circulatory systems. Progr. Cardiovasc. Dis.21, 405–429 (1979).
Ogletree, M. L., A. M. Lefer, J. B. Smith, K. C. Nicolaou: Studies on the protective effect of prostacyclin in acute myocardial ischemia. Europ. J. Pharmacol.56, 95–103 (1979).
Ohlendorf, R., E. Perzborn, K. Schrör: Prevention of infarction-induced decrease in circulating platelet count by prostacyclin. Thrombos. Res.19, 447–453 (1980).
Patscheke, H.: Correlation of activation and aggregation of platelets. Discrimination between anti-activating and anti-aggregating agents. Haemostasis8, 65–81 (1979).
Schrör, K., P. Köhler, M. Müller, P. Rösen: Blood platelets do not provide precursors for vascular PGI2-formation in the intact coronary vascular bed in vitro. Basic Res. Cardiol. (this volume).
Schrör, K., U. Metz, R. Krebs. The bradykinin-induced coronary vasodilation. Evidence for an additional prostacyclin-independent mechanism. Naunyn-Schmiedeberg's Arch. Pharmacol.307, 213–221 (1979).
Schrör, K., E. F. Smith III, M. Bickerton, J. B. Smith, K. G. Nicolaou, R. Magolda, A. M. Lefer: Preservation of ischemic myocardium by pinane thromboxane A2. Amer. J. Physiol.238, H87-H92 (1980).
Smith, J. B., C. M. Ingerman, M. J. Silver: Platelet prostaglandin production and its implications. In: Adv. in Prostaglandin and Thromboxane Res., Vol.2, eds. B. Samuelsson and R. Paoletti, pp. 747–753. Raven Press (New York 1976).
Smith, E. F. III, A. M. Lefer, J. B. Smith: Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Canad. J. Physiol. Pharmacol.58, 294–300 (1980).
Author information
Authors and Affiliations
Additional information
Supported by the Deutsche Forschungsgemeinschaft (SFB 68 A 17)
Rights and permissions
About this article
Cite this article
Köhler, P., Schrör, K. The platelet-perfused in-vitro heart: an alternative model for studying the role of endogenous prostacyclin and thromboxane in control of coronary perfusion. Basic Res Cardiol 76, 463–467 (1981). https://doi.org/10.1007/BF01908344
Issue Date:
DOI: https://doi.org/10.1007/BF01908344